NuGenA (Nurse Led Genetic Counselling and Awareness) Expansion Cohort

OBJECTIVE 1: To determine the efficacy of the NURSE-led cancer genetic clinic program as measured by:

1A: Determining the prevalence of germline mutation in hospital-based patients with ovarian and breast cancers and at-risk individuals in the family.

- 1B: % increase in individuals at risk of developing hereditary cancers through awareness and screening campaigns **compared to** traditional non-concerted hospital-based approaches.
- 1C: Improvement in the uptake of genetic testing and referrals, and risk-reducing interventions.

OBJECTIVE 2:

- **Assess acceptability and embeddedness**
- **Compare local community satisfaction**
- **Study willingness to pay (WTP) for screening and genetic testing**
- **Assessing barriers in rural versus urban and different socio-economic strata**

OBJECTIVE 3:

- **Systematic Biobanking through a structured/NABL accreditable framework (KolGoTrg Biobank – Kolgotrg) - of the samples collected.**

OBJECTIVE 4:

Developing translational research network and pathways to facilitate biomarker research for early detection/prevention for HBOC and Lynch syndrome.



RESULTS

ENROLMENT SITES:

- **AIIMS, NEW DELHI (1/3/25-30/11/25)**
- **NCI-AIIMS, JHAJJAR (1/3/25-30/11/25)**
- **AIIMS, RAIPUR (1/9/25 – 30/11/25)**
- **STRATEGY: NURSE-LED COUNSELING OF CONSECUTIVE, UNSELECTED CASES OF BREAST & OVARIAN CANCERS.**
- **TESTING USING MEDGENOME 140 GENE HEREDITARY CANCER PANEL**











BREAST CANCER





















OVARIAN CANCER





















KEY INSIGHTS

- ✓ **Breast Ca= 20% P/LP, 15% BRCA1/2 (TNBC enriched, ref bias, all reports NA at data-cutoff)**
- ✓ **Ovarian ca= 40% P/LP, 30% BRCA1/2 (all reports NA at data-cutoff)**
- ✓ **Overall BRCA/ non-BRCA =70/30**
- ✓ **VUS=18% (2019=37%): we are improving!**
- ✓ **Median Age for Ca Breast in BRCA2=42 yrs! (low!!)**
- ✓ **No impact of FH in breast ca**
- ✓ **Gradually growing PAN-INDIA Cohort will give a clearer picture of our diverse population.**

(Acknowledgement: Medgenome Labs for supporting this expansion)